Endologix Appoints Graham Phillips as Chief Operating Officer
June 18 2024 - 5:00AM
Business Wire
Endologix LLC, a privately held, global medical device company
dedicated to providing disruptive therapies for the interventional
treatment of vascular disease, is pleased to announce the
appointment of Graham Phillips as its new Chief Operating Officer,
effective immediately.
Graham joins Endologix after having spent over 18 years with
Medtronic, Covidien and Tyco Healthcare where most recently he
served as Vice President of Manufacturing for the Americas East
Region. In this role, he led a large global team across 25
manufacturing sites, from Canada to Brazil, the Caribbean, the
Midwest, and the U.S. East Coast. His responsibilities at Medtronic
were instrumental in shaping the operational success of the
company, significantly contributing to various portfolios that
serviced all operating units. Prior to his extensive career in
Medical Devices, Graham held key manufacturing management positions
at Budelpack (a third-party European contract manufacturer) and
Kraft Foods.
Graham's academic credentials include an undergraduate
bachelor’s degree in Mechanical Engineering from the University of
Teesside, UK, an MBA from the University of Warwick Business
School, UK, and an Advanced Management qualification from Chicago
Booth Business School. He is also a Chartered Engineer with the UK
Institute of Mechanical Engineers and holds a Six Sigma Black Belt,
underscoring his deep commitment to excellence in operational and
manufacturing efficiency.
In his new role as COO at Endologix, Graham will oversee
manufacturing, supply chain, R&D, and quality. He will also be
a vital member of the executive leadership team, reporting directly
to Matt Thompson, MD, President, and CEO of Endologix.
Matt Thompson commented on the appointment, stating, "I am
delighted to welcome Graham to Endologix. His proven leadership and
extensive operational expertise will be invaluable as we continue
to drive growth and innovation within our company."
Regarding his new appointment, Graham Phillips remarked,
“Joining Endologix represents a remarkable opportunity to leverage
my extensive background in operational management to put patients
first through innovation and enhancing our manufacturing and
R&D processes. My commitment is to optimize our operational
capabilities to support Endologix’s mission of delivering
healthcare innovation to improve the lives of patients with
vascular disease."
About Endologix
Endologix LLC is a California-based, global medical device
company dedicated to improving patients’ lives by providing
innovative therapies for the interventional treatment of vascular
disease. Endologix’s therapeutic portfolio includes a variety of
products in various stages of development that are designed to
treat diseases that currently have clinically relevant unmet needs.
Endologix’s commercial products, including the AFX®2 Endovascular
AAA System, ALTO® Abdominal Stent Graft System, and the DETOUR™
System, are designed to treat a range of vascular diseases, from
abdominal aortic aneurysms to lower limb peripheral vascular
disease. Endologix is wholly owned by Deerfield Management, an
investment management firm committed to advancing healthcare
through investment, information, and philanthropy. The company has
offices and manufacturing sites in Irvine, Milpitas and Santa Rosa,
California. To learn more about Endologix, please visit
https://www.endologix.com/.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240618541660/en/
Sandy Prietto 949-595-7240 sprietto@endologix.com